← Browse by Condition
Medical Condition

sjogren syndrome

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2, Phase 1, Phase 4
NCT06991114 Phase 2
Recruiting

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Enrollment
90 pts
Location
United States, Bulga...
Sponsor
Artiva Biotherapeutics, Inc.
View Trial →
NCT03816345 Phase 1
Recruiting

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Enrollment
300 pts
Location
United States, Canad...
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT06794008 Phase 2
Recruiting

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Enrollment
50 pts
Location
China
Sponsor
Peking University People's Hos...
View Trial →
NCT06642870
Recruiting

Rare AutoImmune SElf-management Programme Development

Enrollment
360 pts
Location
United Kingdom
Sponsor
University of the West of Engl...
View Trial →
NCT07153276 Phase 4
Recruiting

TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE

Enrollment
60 pts
Location
Brazil
Sponsor
University of Sao Paulo Genera...
View Trial →